Cancer Screening

Research output: Contribution to journalArticle

Abstract

Cancer screening is a complicated science. Each screening intervention must be carefully assessed before it is widely implemented. A screening test can falsely appear useful as it finds disease at an early stage and leads to intervention and cure. Such a test can be harmful to the population screened if it commonly finds disease that fulfills the pathologic criteria of cancer but behaves indolently (meaning it would never harm the host). Such "pseudo-disease" or "overdiagnosed disease" has been demonstrated in many malignancies including cancers of the lung, breast, and especially the prostate. The nature of each specific screening test and each disease is such that some screened patients may receive unnecessary treatment with all its complications and risk. Alternatively, some screening technologies have been proven useful providing net benefit to the population screened. Often these beneficial technologies are underused. These screening technologies if widely implemented have the potential of saving countless lives. Many available screening tests have tremendous potential in terms of benefit, but have yet to be fully assessed. At the minimum, patients should be informed of what is known, what is not known, and what is believed about these tests.

Original languageEnglish (US)
Pages (from-to)47-53
Number of pages7
JournalSeminars in oncology
Volume31
Issue number2 SUPPL. 4
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Early Detection of Cancer
Technology
Population
Prostate
Lung Neoplasms
Neoplasms
Breast Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Cancer Screening. / Brawley, Otis.

In: Seminars in oncology, Vol. 31, No. 2 SUPPL. 4, 01.01.2004, p. 47-53.

Research output: Contribution to journalArticle

Brawley, Otis. / Cancer Screening. In: Seminars in oncology. 2004 ; Vol. 31, No. 2 SUPPL. 4. pp. 47-53.
@article{256deaffbe8c4afb93d98bea6a5419e3,
title = "Cancer Screening",
abstract = "Cancer screening is a complicated science. Each screening intervention must be carefully assessed before it is widely implemented. A screening test can falsely appear useful as it finds disease at an early stage and leads to intervention and cure. Such a test can be harmful to the population screened if it commonly finds disease that fulfills the pathologic criteria of cancer but behaves indolently (meaning it would never harm the host). Such {"}pseudo-disease{"} or {"}overdiagnosed disease{"} has been demonstrated in many malignancies including cancers of the lung, breast, and especially the prostate. The nature of each specific screening test and each disease is such that some screened patients may receive unnecessary treatment with all its complications and risk. Alternatively, some screening technologies have been proven useful providing net benefit to the population screened. Often these beneficial technologies are underused. These screening technologies if widely implemented have the potential of saving countless lives. Many available screening tests have tremendous potential in terms of benefit, but have yet to be fully assessed. At the minimum, patients should be informed of what is known, what is not known, and what is believed about these tests.",
author = "Otis Brawley",
year = "2004",
month = "1",
day = "1",
doi = "10.1053/j.seminoncol.2004.02.009",
language = "English (US)",
volume = "31",
pages = "47--53",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 4",

}

TY - JOUR

T1 - Cancer Screening

AU - Brawley, Otis

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Cancer screening is a complicated science. Each screening intervention must be carefully assessed before it is widely implemented. A screening test can falsely appear useful as it finds disease at an early stage and leads to intervention and cure. Such a test can be harmful to the population screened if it commonly finds disease that fulfills the pathologic criteria of cancer but behaves indolently (meaning it would never harm the host). Such "pseudo-disease" or "overdiagnosed disease" has been demonstrated in many malignancies including cancers of the lung, breast, and especially the prostate. The nature of each specific screening test and each disease is such that some screened patients may receive unnecessary treatment with all its complications and risk. Alternatively, some screening technologies have been proven useful providing net benefit to the population screened. Often these beneficial technologies are underused. These screening technologies if widely implemented have the potential of saving countless lives. Many available screening tests have tremendous potential in terms of benefit, but have yet to be fully assessed. At the minimum, patients should be informed of what is known, what is not known, and what is believed about these tests.

AB - Cancer screening is a complicated science. Each screening intervention must be carefully assessed before it is widely implemented. A screening test can falsely appear useful as it finds disease at an early stage and leads to intervention and cure. Such a test can be harmful to the population screened if it commonly finds disease that fulfills the pathologic criteria of cancer but behaves indolently (meaning it would never harm the host). Such "pseudo-disease" or "overdiagnosed disease" has been demonstrated in many malignancies including cancers of the lung, breast, and especially the prostate. The nature of each specific screening test and each disease is such that some screened patients may receive unnecessary treatment with all its complications and risk. Alternatively, some screening technologies have been proven useful providing net benefit to the population screened. Often these beneficial technologies are underused. These screening technologies if widely implemented have the potential of saving countless lives. Many available screening tests have tremendous potential in terms of benefit, but have yet to be fully assessed. At the minimum, patients should be informed of what is known, what is not known, and what is believed about these tests.

UR - http://www.scopus.com/inward/record.url?scp=2342555692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342555692&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.02.009

DO - 10.1053/j.seminoncol.2004.02.009

M3 - Article

C2 - 15124134

AN - SCOPUS:2342555692

VL - 31

SP - 47

EP - 53

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 4

ER -